Podcast appearances and mentions of John B Buse

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you'll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you'll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/YYH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in the treatment of patients with diabetes. Upon completion of this activity, participants should be better able to: Apply current guidelines for the use of GLP-1 RAs in appropriately selected patients with T2DM, Differentiate current and emerging GLP-1 RAs from each other and from other agents used to treat T2DM, Identify GLP-1 RAs indicated for CV risk reduction in patients with T2DM, Implement shared decision-making with patients with T2DM initiating GLP-1 RA therapy

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.

Go online to PeerView.com/XRN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in endocrinology discusses the clinical potential of SGLT2 inhibitors for the prevention and treatment of kidney disease in patients with type 2 diabetes. Upon completion of this activity, participants should be better able to: Review the proposed mechanism(s) that support the clinical potential of SGLT2 inhibitors to provide renal protection in patients with type 2 diabetes, Assess the evidence evaluating the potential of SGLT2 inhibitors to prevent and/or treat kidney disease in patients with type 2 diabetes.